Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7779178 | 0.82 | CA5A (0.50) | CA5ALMNATTRTSHRALDH1A1 | |
| SCHEMBL13125475 | 0.80 | NPFFR2 (0.42) | CA5ALMNAMAPTRAB9AGAA | |
| SCHEMBL3243039 | 0.80 | TTR (0.62) | CA5ALMNATTRTSHRALDH1A1 | |
| SCHEMBL984068 | 0.80 | TTR (0.39) | TTRTSHRALDH1A1MAPTHPGD | |
| SCHEMBL1573147 | 0.80 | TTR (0.62) | CA5ALMNATTRTSHRALDH1A1 | |
| SCHEMBL9417255 | 0.78 | TTR (0.60) | CA5ALMNATTRTSHRALDH1A1 | |
| SCHEMBL1003805 | 0.78 | LMNA (0.49) | LMNATTRTSHRALDH1A1MAPT | |
| SCHEMBL5872407 | 0.78 | CA5A (0.46) | CA5ALMNATTRTSHRALDH1A1 | |
| SCHEMBL2866567 | 0.78 | HSD11B1 (0.48) | CA5ALMNATTRALDH1A1KDM4E | |
| SCHEMBL15199066 | 0.78 | CA5A (0.46) | CA5ALMNATTRTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58162577-A | — | — | None | — | — | JP | disclosed |
| US-9951060-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-1092721-B1 | Chiral glucosides and their use as chiral dopants for the production of cholesteric liquid crystalline compositions | BASF AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-0089650-B1 | PROCESS FOR PRODUCING ANTIFUNGAL PYRIDAZINONE DERIVATIVES AND CERTAIN NOVEL COMPOUNDS PRODUCED BY SUCH A PROCESS | SANKYO COMPANY LIMITED (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4603201-A | Process for producing antifungal oyridazinone derivatives | SANKYO COMPANY LIMITED (JP) | 1986-07-29 | — | — | US | disclosed |
| EP-0089650-A1 | Process for producing antifungal pyridazinone derivatives and certain novel compounds produced by such a process | SANKYO COMPANY LIMITED (JP) | 1983-09-28 | — | — | EP | disclosed |
| JP-S58162577-A | PREPARATION OF 6-PHENYLPYRIDAZINONE COMPOUND | SANKYO CO LTD | 1983-09-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, CHRM5 | CA5A 1000/4885LMNA 4251/4885TTR 4084/4885 |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, TRPM2 | CA5A 1262/4885LMNA 4304/4885TTR 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.